New candidates in Zealand’s peptide pipeline
Danish biotech company Zealand Pharma’s pipeline contains several research projects including a phase I obesity candidate that, in the preclinical version, proved more effective than one of Novo’s drugs. Zealand is also turning to another Danish company’s preserves.
BY MARTIN HAVTORN PETERSEN
Last year, Zealand Pharma expanded its clinical development pipeline when the partner, German Boehringer Ingelheim, took two projects to phase I.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand initiates obesity study together with Boehringer
For abonnenter
